#phge hashtag - Bluesky

BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency BiomX (NYSE American: PHGE) received a March 25, 2026 notice that it does not meet NYSE American stockholders' equity minimums in Sections 1003(a)(i)-(iii). The company must submit a compliance plan by April 24, 2026 to regain compliance by September 25, 2027.The Notice does not affect current listing or trading and the company previously disclosed a going concern paragraph in its 2025 audited financial statements.

1 week ago

#PHGE BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency

www.stocktitan.net/news/PHGE/biom-x-inc-rec...

0 0 0 0

BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations BiomX (NYSE: PHGE) launched X Security & Defense LTD. in Israel on March 26, 2026 and will finance 2026 operations with over $3 million from internal funds. The company signed a non‑binding LOI for exclusive Israel distribution of an advanced aerial firefighting drone system.BiomX aims to commercialize security, defense and first‑response technologies amid growing UAV emergency markets (UAV emergency responders: $3.2B 2023 → $9.6B 2032; firefighting drones: $1.8B 2023 → $4.5B 2032) and cites Israeli government emergency budgets exceeding $500 million.

1 week ago

#PHGE BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations

www.stocktitan.net/news/PHGE/biom-x-launche...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

BiomX CEO Updates Shareholders on Company Transformation and Future Growth The CEO of BiomX shares strategic changes to strengthen the company, focusing on financial restructuring and pursuing new opportunities in advanced technologies.

BiomX CEO Updates Shareholders on Company Transformation and Future Growth #USA #Dover #BiomX #Michael_Oster #PHGE

0 0 0 0

BiomX CEO Issues Letter to Stockholders BiomX (NYSE American: PHGE) CEO Michael Oster outlined a strategic and financial reset on March 19, 2026, aimed at stabilizing finances, simplifying capital structure, and unlocking future growth.Key action: warrants from a December 2025 investment were amended to a one-year exercise period with an $1.00 exercise price, per the Form 8-K. Management is cutting non-essential costs, closing a Maryland facility, engaging banks and investors, and exploring repositioning toward defense-related opportunities.

2 weeks ago

#PHGE BiomX CEO Issues Letter to Stockholders

www.stocktitan.net/news/PHGE/biom-x-ceo-iss...

0 0 0 0

BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth BiomX (NYSE American: PHGE) announced on March 9, 2026 the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer to support the company’s next growth phase. Both executives bring senior experience in M&A, corporate strategy, finance, and capital markets.BiomX is a clinical-stage company developing natural and engineered phage therapies targeting harmful bacteria in chronic diseases; the new leaders will focus on execution, capital strategy, and investor engagement.

3 weeks ago

#PHGE BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

www.stocktitan.net/news/PHGE/biom-x-names-m...

0 0 0 0

2 months ago

Just In: ( NYSE: #PHGE ) US Companies Moving the Markets, Morning edition <br>Wed, Jan 28, 2026 as of 10.00 am ET

0 0 0 0

2 months ago

Just In: ( NYSE: #PHGE ) US Companies Moving the Markets, Evening edition <br>Tue, Jan 27, 2026 as of 4:00 pm ET

0 0 0 0

2 months ago

NEWS: ( NYSE: #PHGE ) BiomX Issues Statement Regarding Recent Common Stock Trading Activity

0 0 0 0

BiomX Announces $3.0 Million Private Placement BiomX (NYSE American: PHGE) announced a private placement expected to raise approximately $3.0 million in gross proceeds on December 29, 2025. The company said proceeds will support assessment of opportunities to advance BX011 and continued evaluation of strategic alternatives. H.C. Wainwright & Co. served as exclusive placement agent. Amounts are before placement agent fees and offering expenses.

3 months ago

#PHGE BiomX Announces $3.0 Million Private Placement

www.stocktitan.net/news/PHGE/biom-x-announc...

0 0 0 0

BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review BiomX (NYSE American: PHGE) announced on December 8, 2025 that it will discontinue the Phase 2b trial of nebulized phage therapy BX004 in cystic fibrosis after an internal review and recommendations from the independent Data Monitoring Committee following unusually high rates of adverse events.The company said it will implement cost‑cutting measures, including a significant workforce reduction, and review strategic alternatives while refocusing development efforts on its bacteriophage program BX011 for Staphylococcus aureus diabetic foot infections, subject to available resources.

3 months ago

#PHGE BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

www.stocktitan.net/news/PHGE/biom-x-announc...

0 0 0 0

Emmanuele Severi

@emmseveri.bsky.social

4 months ago

Systematic discovery of TIR-based immune signaling systems in bacteria Toll/interleukin-1 receptor (TIR) domains are important for immune signaling across humans, plants and bacteria. These domains were recently found to produce immune signaling molecules in plant immuni...

#microsky #phagesky #phge defence

Preprint from the @soreklab.bsky.social reporting a plethora of novel TIR-based immune signalling systems

www.biorxiv.org/content/10.6...

17 4 0 0

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis BiomX (NYSE American: PHGE) said the FDA is continuing to evaluate the nebulizer device used in its BX004 Phase 2b cystic fibrosis trial and the company is working with the device manufacturer to provide requested information to lift the clinical hold. An independent Data Monitoring Committee (DMC) completed a safety review after adverse events and recommended the study continue with adjusted dosing. BiomX will update the protocol and now expects topline results in Q2 2026, with U.S. enrollment to resume once device questions are resolved.

4 months ago

#PHGE BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

www.stocktitan.net/news/PHGE/biom-x-provide...

0 0 0 0

BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections BiomX Inc. (NYSE American: PHGE) (“BiomX” or the

4 months ago

#PHGE BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections

www.stocktitan.net/news/PHGE/biom-x-announc...

1 1 0 0

BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways BiomX believes that it has fully addressed the FDA’s queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clarifications on the nebulizer has also been addressed In parallel, new written FDA feedback

5 months ago

#PHGE BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

www.stocktitan.net/news/PHGE/biom-x-provide...

0 0 0 0

FDA Places Clinical Hold on BiomX's Cystic Fibrosis Trial BX004 - European Study Continues Unaffected FDA clinical hold focuses solely on third-party nebulizer device for BX004 CF therapy, not the drug itself. BiomX continues EU trial enrollment while addressing FDA queries with submitted data.

7 months ago

#PHGE BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

www.stocktitan.net/news/PHGE/biom-x-provide...

0 0 0 0

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates BiomX (NYSE American: PHGE) reported significant clinical progress and Q2 2025 financial results. The company achieved positive Phase 2 results for BX211 in diabetic foot osteomyelitis, demonstrating >40% wound size reduction versus placebo. Their BX004 program showed promising results with a ~500-fold bacterial reduction in cystic fibrosis patients, as published in Nature Communications.The company has initiated patient dosing in the Phase 2b trial of BX004, with topline results expected in Q1 2026. Financial highlights include a cash balance of $15.2 million as of June 30, 2025, with funding runway into Q1 2026. Q2 2025 showed reduced operating expenses, with R&D expenses at $5.0 million (down from $6.9M) and net loss of $6.0 million.

7 months ago

#PHGE BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

www.stocktitan.net/news/PHGE/biom-x-reports...

0 0 0 0

7 months ago

News; ( NYSE: #PHGE ) BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

0 0 0 0

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis BiomX (NYSE American: PHGE) has initiated patient dosing in its Phase 2b trial of BX004, a phage therapy targeting antibiotic-resistant Pseudomonas aeruginosa infections in cystic fibrosis patients. The randomized, double-blind, placebo-controlled study will evaluate approximately 60 patients over an 8-week treatment period.The trial follows promising Phase 1b/2a results where 14.3% of patients achieved complete bacterial clearance after just 10 days of treatment. The company expects topline results in Q1 2026 and anticipates FDA feedback in H2 2025 regarding the use of real-world evidence linking bacterial reduction to clinical outcomes. BX004 has already received Fast Track and Orphan Drug designations.

8 months ago

#PHGE BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

www.stocktitan.net/news/PHGE/biom-x-announc...

0 0 0 0

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis BiomX (NYSE American: PHGE) has published Phase 1b/2a Part 1 trial results of its phage cocktail BX004 in Nature Communications, demonstrating significant efficacy against antibiotic-resistant P. aeruginosa infections in cystic fibrosis patients.The study revealed a remarkable 500-fold (2.7 log₁₀) bacterial reduction compared to placebo, with no emerging resistance. Key findings include a strong safety profile, successful bacterial reduction achieved at day 15, and therapeutic phages reaching and persisting at infection sites. The treatment demonstrated favorable microbiome composition shifts and maintained efficacy where traditional antibiotics often fail.BiomX is currently advancing its Phase 2b trial of BX004, with topline results expected in Q1 2026.

8 months ago

#PHGE BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

www.stocktitan.net/news/PHGE/biom-x-announc...

0 0 0 0

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026 In April 2025, shareholders approved exercise of warrants

10 months ago

#PHGE BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

www.stocktitan.net/news/PHGE/biom-x-reports...

0 0 0 0

Critical Audit Alert: BiomX Receives Going Concern Opinion - What This Means BiomX's auditors raise going concern qualification in latest financial audit. Key details on financial stability and NYSE compliance measures revealed.

1 year ago

#PHGE BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

www.stocktitan.net/news/PHGE/biom-x-announc...

0 0 0 0

Major Clinical Success: BiomX's New Drug Shows Promise in Preventing Diabetic Amputations Novel therapy BX211 achieves significant ulcer reduction in Phase 2 DFO trial, marking potential breakthrough for diabetic foot treatment. Full analysis inside.

1 year ago

#PHGE BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

www.stocktitan.net/news/PHGE/biom-x-announc...

0 0 0 0

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates BiomX (NYSE: PHGE) announced its Q4 and full year 2024 financial results, highlighting key developments in its phage therapy programs. The company secured $12 million in financing in February 2025 to support its Phase 2b study of BX004. Key financial metrics include:- Cash balance of $18.0 million as of December 31, 2024- R&D expenses increased to $24.7 million in 2024- Net loss decreased to $17.7 million in 2024- Operating cash burn of $37 million in 2024Clinical Updates:BX211 Phase 2 topline results for diabetic foot osteomyelitis expected by end of March 2025BX004 Phase 2b topline results for cystic fibrosis anticipated in Q1 2026Received $36.8 million in non-dilutive funding from DHA for BX211 trial

1 year ago

#PHGE BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

www.stocktitan.net/news/PHGE/biom-x-reports...

0 0 0 0

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million BiomX Inc. (NYSE American: PHGE) has secured $12 million in financing through a series of offerings, including a registered direct offering and concurrent private placement. The funding will support the advancement of their BX004 program through Phase 2b study in cystic fibrosis patients, with topline results expected in Q1 2026.The offerings were led by Deerfield Management Company with significant participation from the Cystic Fibrosis Foundation and Nantahala Capital. The financing includes the purchase of 3,633,514 shares of common stock at $0.9306 per share, along with warrants for additional shares. The company will also analyze real-world evidence exploring the relationship between P. aeruginosa reduction and clinical outcomes in CF patients.

1 year ago

#PHGE BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

www.stocktitan.net/news/PHGE/biom-x-announc...

0 0 0 0